Motilal Oswal has initiated a 'Buy' rating on Ipca Laboratories with a price target of Rs 2,060 following a strong first-quarter financial performance. The brokerage highlights robust export growth and improved margins as key drivers for the company's upgraded guidance, though investors may track domestic performance and valuation multiples closely.
Motilal Oswal has initiated coverage on Ipca Laboratories with a 'Buy' rating and a price target of Rs 2,060 per share. This move follows the company's strong performance in the first quarter of the 2027 fiscal year, where the firm reported financial results that surpassed expectations.
Ipca Laboratories delivered a strong operational showing in the first quarter, with revenue rising 20.76% year-on-year to Rs 2,788.10 crore. Profit After Tax also showed significant growth, increasing by 72.33% compared to the same period last year to reach Rs 401.89 crore. This performance was largely supported by robust sales in the export generics segment, particularly in branded exports, which have seen consistent expansion for several quarters.
Following these results, the company management has upwardly revised its guidance for the 2027 fiscal year. The company now expects revenue to grow between 14% and 16%, while targeting an EBITDA margin of 23%. These revisions reflect confidence in continued operating leverage and the scalability of the current business model. Furthermore, the company improved its balance sheet position significantly during the previous financial year by repaying all its outstanding US dollar-denominated loans.
While the brokerage report highlights the company's growth trajectory, there are factors investors typically watch in this sector. For instance, while export performance has been strong, the company’s domestic formulation growth has at times trailed the growth rate of the broader Indian Pharmaceutical Market (IPM), suggesting a slight pressure on local market share. Additionally, the performance of its subsidiary, Unichem Laboratories, is a monitorable area, as its EBITDA margins have recently hovered near 12.1%, slightly below the desired range of 12-13%.
From a valuation perspective, the stock is currently trading at a price-to-earnings (P/E) multiple of approximately 32-34 times. Investors may track whether the company can maintain its current pace of growth to justify these valuation levels, as high premiums can lead to price volatility if future earnings do not meet the upgraded guidance. As with any pharmaceutical company, broader sector risks such as regulatory changes in key export markets, currency fluctuations, and raw material cost pressures remain relevant factors that can influence financial performance.
The key monitorables for the coming quarters will be the execution of the raised guidance, the trajectory of domestic market share, and improvements in the operational efficiency of the Unichem subsidiary.